In consonance with these actions, circulating CCL18 levels have been demonstrated to be a biomarker for disease activity and outcome in various fibrotic diseases [19, 43, 44], as well as in some eosinophilic disorders [30, 45, 46]. This evidence concerns the gene CCL18 and eosinophil disorder.